 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
11 News |  |
- |||| Tazverik (tazemetostat) / Ipsen
Trial completion, Combination therapy, Epigenetic controller, Metastases: E7438-G000-101: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL (clinicaltrials.gov) - Nov 16, 2021
P1/2, N=420, Completed, Sponsor: Epizyme, Inc.
Active, not recruiting --> Completed
- || Tazverik (tazemetostat) / Ipsen
Trial completion date, Trial primary completion date, Combination therapy, Epigenetic controller, Metastases: E7438-G000-101: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL (clinicaltrials.gov) - Aug 18, 2021
P1/2, N=420, Active, not recruiting, Sponsor: Epizyme, Inc.
Active, not recruiting --> Completed Trial completion date: May 2021 --> Nov 2021 | Trial primary completion date: May 2021 --> Nov 2021
- || Tazverik (tazemetostat) / Ipsen
Trial primary completion date, Combination therapy, Epigenetic controller, Metastases: E7438-G000-101: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL (clinicaltrials.gov) - Jan 7, 2021
P1/2, N=420, Active, not recruiting, Sponsor: Epizyme, Inc.
Trial completion date: May 2021 --> Nov 2021 | Trial primary completion date: May 2021 --> Nov 2021 Trial primary completion date: Nov 2019 --> May 2021
- | Tazverik (tazemetostat) / Ipsen
Enrollment closed, Trial completion date, Combination therapy, Epigenetic controller, Metastases: E7438-G000-101: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL (clinicaltrials.gov) - Jul 9, 2019
P1/2, N=420, Active, not recruiting, Sponsor: Epizyme, Inc.
Trial primary completion date: Nov 2019 --> May 2021 Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Jul 2021
- ||| Tazverik (tazemetostat) / Ipsen
Enrollment change, Combination therapy, Epigenetic controller, Metastases: E7438-G000-101: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL (clinicaltrials.gov) - Mar 30, 2017
P1/2, N=420, Recruiting, Sponsor: Epizyme, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Jul 2021 N=350 --> 420
- || Tazverik (tazemetostat) / Ipsen
Trial primary completion date, Combination therapy, Epigenetic controller, Metastases: E7438-G000-101: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL (clinicaltrials.gov) - Dec 9, 2016
P1/2, N=350, Recruiting, Sponsor: Epizyme, Inc.
N=350 --> 420 Trial primary completion date: Nov 2017 --> Nov 2019
- ||| Tazverik (tazemetostat) / Ipsen
Enrollment change, Trial primary completion date, Combination therapy, Epigenetic controller, Metastases: E7438-G000-101: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL (clinicaltrials.gov) - Aug 31, 2016
P1/2, N=350, Recruiting, Sponsor: Epizyme, Inc.
Trial primary completion date: Nov 2017 --> Nov 2019 N=225 --> 350 | Trial primary completion date: Jul 2017 --> Nov 2017
- ||| Tazverik (tazemetostat) / Ipsen
Enrollment change, Trial primary completion date, Combination therapy, Epigenetic controller, Metastases: E7438-G000-101: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL (clinicaltrials.gov) - Jun 16, 2015
P1/2, N=225, Recruiting, Sponsor: Epizyme, Inc.
N=225 --> 350 | Trial primary completion date: Jul 2017 --> Nov 2017 N=154 --> 225 | Trial primary completion date: Mar 2015 --> Jul 2017
- || Tazverik (tazemetostat) / Ipsen
Trial primary completion date, Combination therapy, Epigenetic controller, Metastases: E7438-G000-101: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL (clinicaltrials.gov) - Aug 22, 2014
P1/2, N=154, Recruiting, Sponsor: Eisai Limited
N=154 --> 225 | Trial primary completion date: Mar 2015 --> Jul 2017 Trial primary completion date: Mar 2017 --> Mar 2015
- ||||| Tazverik (tazemetostat) / Ipsen
New P1/2 trial, Combination therapy, Epigenetic controller, Metastases: E7438-G000-101: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL (clinicaltrials.gov) - Jul 10, 2013
P1/2, N=154, Recruiting, Sponsor: Eisai Limited